East Coast Asset Management. Lowers stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : East Coast Asset Management. reduced its stake in Becton Dickinson and Co by 19.37% during the most recent quarter end. The investment management company now holds a total of 20,882 shares of Becton Dickinson and Co which is valued at $3,623,445 after selling 5,018 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Becton Dickinson and Co makes up approximately 1.90% of East Coast Asset Management.’s portfolio.

Other Hedge Funds, Including , Staley Capital Advisers Inc reduced its stake in BDX by selling 325 shares or 14.29% in the most recent quarter. The Hedge Fund company now holds 1,950 shares of BDX which is valued at $338,774. Becton Dickinson and Co makes up approx 0.03% of Staley Capital Advisers Inc’s portfolio.Tdam Usa reduced its stake in BDX by selling 933 shares or 3.7% in the most recent quarter. The Hedge Fund company now holds 24,304 shares of BDX which is valued at $4,222,334. Becton Dickinson and Co makes up approx 0.20% of Tdam Usa’s portfolio.Candriam Luxembourg S.c.a. reduced its stake in BDX by selling 13,231 shares or 61.05% in the most recent quarter. The Hedge Fund company now holds 8,440 shares of BDX which is valued at $1,473,033. Becton Dickinson and Co makes up approx 0.04% of Candriam Luxembourg S.c.a.’s portfolio.

Becton Dickinson and Co opened for trading at $172.54 and hit $173.3413 on the upside on Wednesday, eventually ending the session at $173.11, with a gain of 0.19% or 0.33 points. The heightened volatility saw the trading volume jump to 5,25,170 shares. Company has a market cap of $36,860 M.

On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.

Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.